Diagnostics In Brief
This article was originally published in The Gray Sheet
Executive Summary
BioNanomatrix, NCI collaborate: Genome imaging and analytic platform developer BioNanomatrix inks a multi-year research and development agreement with the National Cancer Institute, firm announces Jan. 18. The company will work with NCI's Radiation Biology Branch to develop tools to detect and quantify DNA damage caused by cancer therapies in order to optimize radiation dosing. BioNanomatrix's Nanoanalyzer whole genome analyzer unwinds DNA from its supercoiled structure to enable the identification of specific DNA aberrations. Pending successful results assessing radiation-induced damage, the firm plans to study DNA aberrations resulting from chemotherapy. BioNanomatrix has an exclusive license to use the technologies from Princeton University...